Posted by Michael Wonder on 01 Sep 2021
Amylyx Pharmaceuticals announces Health Canada accepts for review the new drug submission for AMX0035 for the treatment of ALS
31 August 2021 - Amylyx Pharmaceuticals today announced that Health Canada has accepted for review the new drug submission for AMX0035 for the treatment of amyotrophic lateral sclerosis.
CENTAUR was a Phase 2, multi-centre trial in 137 participants with amyotrophic lateral sclerosis encompassing a 6 month randomised placebo controlled phase and an open-label long-term follow-up phase.
